Xcout Intel
Galecto Inc.
Galecto is a clinical-stage biotechnology company focused on developing novel drugs for the treatment of fibrosis, inflammation, and other serious human diseases. Incorporated in the US with operating headquarters in Copenhagen, Denmark, the company is backed by investors such as Novo Holdings and OrbiMed.
Subscribe to see Galecto Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Galecto Inc. at a glance
Galecto Inc. is a biotechnology company headquartered in Denmark. It has raised at least $713.3M across the 4 funding rounds on record. Its most recent funding round raised $285M in November 2025. Xcout tracks 23 named people at Galecto Inc., including Hans T. Schambye (President & Chief Executive Officer).
Galecto Inc. leadership
- Hans T. SchambyePresident & Chief Executive Officer
- Jennifer JarrettChief Executive Officer & Board Director
- Sherwin SattarzadehChief Operating Officer
- Becker HewesChief medical Officer
- Jim BakerChief Corporate Affairs Officer
- Brian BurkavageSenior Vice President, Finance
17 more named people on record for Galecto Inc., with roles, board committees and tenure — see the full roster →
Galecto Inc. funding rounds
At least $713.3M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $285M | — | |
| Series C | $285M | 14 named | |
| — | $64.2M | 14 named | |
| SEC Form D filing | $79.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Galecto Inc. competitors
A few of Galecto Inc.'s closest competitors — see the full list of competitors and alternatives →
Galecto Biotech is a biotechnology company developing small-molecule inhibitors targeting galectin proteins and related pathways, with applications in fibrotic diseases and cancer. Its products are intended for patients and healthcare providers, particularly in areas with limited treatment options.
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Chemomab is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. Based in Tel Aviv, Israel, the company builds its treatments on unique scientific insights.
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Get Galecto Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Galecto Inc. in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access